Pharmacyte Biotech, Inc. (PMCB) - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Pharmacyte Biotech, Inc. on February 17, 2022, covering events occurring on February 13 and February 15, 2022. The Company is incorporated in Nevada and its common stock trades on the Nasdaq Capital Market under the symbol "PMCB".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report addresses corporate governance and listing compliance rather than financial performance.
Material Changes
- Board Composition: Thomas C.K. Yuen, an independent member of the Board of Directors and Chairman of the Nominating Committee, passed away on February 13, 2022.
- Listing Compliance: As a result of Mr. Yuen's death, the Company is temporarily not in compliance with Nasdaq Listing Rule 5605(b)(1), which requires a majority of the Board to be comprised of independent directors.
Outlook, Management Commentary, and Risks
Management notified Nasdaq of the non-compliance on February 15, 2022. The Company has an automatic cure period under Nasdaq Listing Rule 5605(b)(1)(A) to regain compliance. Management expects to fill the vacancy with a new independent director who satisfies applicable requirements prior to the expiration of the cure period. No other risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Verify the timeline for appointing a new independent director to restore Board majority independence.
- Confirm the Company's continued compliance status with Nasdaq Listing Rule 5605(b)(1) in subsequent filings.
- Review the composition of the Board's Compensation and Nominating Committees following the vacancy.